Solange Peters

514 total citations · 1 hit paper
7 papers, 142 citations indexed

About

Solange Peters is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Solange Peters has authored 7 papers receiving a total of 142 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Solange Peters's work include Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Solange Peters is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Research Studies (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Solange Peters collaborates with scholars based in United States, Switzerland and Spain. Solange Peters's co-authors include Fred R. Hirsch, Luis Paz‐Ares, Federico Cappuzzo, Pasi A. Jänne, Marina Chiara Garassino, Shun Lu, Jianjun Zhang, Tony Mok, Filippo de Marinis and Ramaswamy Govindan and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Solange Peters

6 papers receiving 141 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New promises and challenges in the treatment of advanced non-small-cell lung cancer

2024 116 citations Luis Paz‐Ares, Federico Cappuzzo et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Solange Peters United States	4	64	52	50	30	22	7	142
Patricia Iranzo Spain	7	108 1.7×	25 0.5×	66 1.3×	30 1.0×	34 1.5×	22	158
Jacqueline H. Starrett United States	4	95 1.5×	41 0.8×	73 1.5×	28 0.9×	15 0.7×	5	136
Guanhua Yu China	4	71 1.1×	50 1.0×	29 0.6×	31 1.0×	24 1.1×	10	138
Deukchae Na South Korea	7	67 1.0×	70 1.3×	20 0.4×	17 0.6×	43 2.0×	11	136
Shen Lao China	6	89 1.4×	50 1.0×	39 0.8×	52 1.7×	19 0.9×	11	172
Miguel‐Ángel Berciano‐Guerrero Spain	7	85 1.3×	70 1.3×	23 0.5×	62 2.1×	27 1.2×	28	156
Hui Yi Chew Australia	5	36 0.6×	33 0.6×	38 0.8×	17 0.6×	13 0.6×	8	94
Nicole Fuhrich Germany	3	56 0.9×	22 0.4×	22 0.4×	44 1.5×	14 0.6×	3	100
P. Damiano Italy	4	52 0.8×	36 0.7×	58 1.2×	10 0.3×	20 0.9×	5	94
Joana L. Mora United States	2	47 0.7×	47 0.9×	36 0.7×	11 0.4×	12 0.5×	3	95

Countries citing papers authored by Solange Peters

Since Specialization

Citations

This map shows the geographic impact of Solange Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Solange Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Solange Peters more than expected).

Fields of papers citing papers by Solange Peters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Solange Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Solange Peters. The network helps show where Solange Peters may publish in the future.

Co-authorship network of co-authors of Solange Peters

This figure shows the co-authorship network connecting the top 25 collaborators of Solange Peters. A scholar is included among the top collaborators of Solange Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Solange Peters. Solange Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Safi, Mohammed, Fred R. Hirsch, Shun Lu, et al.. (2025). Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions. Nature Reviews Clinical Oncology. 22(3). 200–214. 10 indexed citations

Skoulidis, Ferdinandos, Ticiana Leal, Stephen V. Liu, et al.. (2025). Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1 , or KRAS : the TRITON study. Therapeutic Advances in Medical Oncology. 17. 22831347–22831347.

Peters, Solange, Roy S. Herbst, Hidehito Horinouchi, et al.. (2025). Abstract CT051: SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC. Cancer Research. 85(8_Supplement_2). CT051–CT051. 6 indexed citations

Paz‐Ares, Luis, Stephen V. Liu, Solange Peters, et al.. (2025). Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.. Journal of Clinical Oncology. 43(16_suppl). 8006–8006. 2 indexed citations

Peters, Solange, et al.. (2024). DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC).. Journal of Clinical Oncology. 42(16_suppl). TPS8127–TPS8127. 1 indexed citations

Paz‐Ares, Luis, et al.. (2024). New promises and challenges in the treatment of advanced non-small-cell lung cancer. The Lancet. 404(10454). 803–822. 116 indexed citations breakdown →

Gridelli, Cesare, Solange Peters, Tony Mok, et al.. (2023). Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT). Lung Cancer. 187. 107441–107441. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact